Mark Harvey
Corporate Officer/Principal en The University of Queensland .
Perfil
Mark Harvey is an Adjunct Associate Professor at The University of Queensland.
He previously worked as an Independent Non-Executive Director at Nuwellis, Inc. in 2012, as well as a Director at Pathway Therapeutics, Inc. and Pathway Therapeutics Ltd.
He was also a Director at Osprey Medical, Inc. from 2007 to 2011.
Additionally, he served as the Managing Director at Symbiosis Group Ltd.
and was a Partner at CM Capital Investments Pty Ltd.
from 2010 to 2012.
He was also an Investment Committee Member at ANU Connect Ventures Pty Ltd.
Dr. Harvey received his undergraduate, MBA, and doctorate degrees from The University of Queensland.
Cargos activos de Mark Harvey
Empresas | Cargo | Inicio |
---|---|---|
The University of Queensland | Corporate Officer/Principal | - |
Antiguos cargos conocidos de Mark Harvey.
Empresas | Cargo | Fin |
---|---|---|
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Director of Investments | 20/11/2012 |
NUWELLIS, INC. | Director/Miembro de la Junta | 12/11/2012 |
OSPY MEDI CDI | Director/Miembro de la Junta | - |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Inversor de Capital Privado | 01/04/2006 |
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Director/Miembro de la Junta | - |
Formación de Mark Harvey.
The University of Queensland | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
NUWELLIS, INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
CM Capital Investments Pty Ltd.
CM Capital Investments Pty Ltd. Investment ManagersFinance CM Capital Investments Pty Ltd is a venture capital firm, a subsidiary of Talu Ventures Pty Ltd founded in 1998 by Michael Begun and Carmel J. Hillyard, The firm is headquartered in Brisbane. | Finance |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
Osprey Medical, Inc.
Osprey Medical, Inc. Medical SpecialtiesHealth Technology Osprey Medical, Inc. engages in the development to prevent harmful effect of x-ray dye used during angiographic imaging procedures. Its product includes Dyevert system, which is designed to reduce the amount of dye contrast injected into the patients during standard cardiovascular procedures. The company was founded by Frank Solomon, David Kaye, and James Edward Shapland on August 31, 2005 and is headquartered in Minnetonka, MN. | Health Technology |
ANU Connect Ventures Pty Ltd.
ANU Connect Ventures Pty Ltd. Investment ManagersFinance ANU Connect Ventures Pty Ltd (ANU Connect Ventures) is a venture capital subsidiary of Australian National University founded in 2005. The firm is headquartered in Canberra, Australia. | Finance |
Symbiosis Group Ltd.
Symbiosis Group Ltd. Investment ManagersFinance Symbiosis Group Ltd. (Symbiosis) is a venture capital subsidiary of UniQuest Pty Ltd. founded in 2004.The firm headquartered in Queensland, Australia. | Finance |
- Bolsa de valores
- Insiders
- Mark Harvey